Evidence for novel cannabinoid receptors

Cannabinoids, including the bioactive constituents of the marijuana plant, their synthetic analogs, and endogenous lipids with cannabinoid-like activity, produce their biological effects by interacting with specific receptors. To date, two G protein-coupled cannabinoid receptors have been identified...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology & therapeutics (Oxford) 2005-05, Vol.106 (2), p.133-145
Main Authors: Begg, Malcolm, Pacher, Pál, Bátkai, Sándor, Osei-Hyiaman, Douglas, Offertáler, László, Mo, Fong Ming, Liu, Jie, Kunos, George
Format: Article
Language:English
Subjects:
Animals
Brain - drug effects
Brain - metabolism
Cannabinoid Receptor Antagonists
Cannabinoids - antagonists & inhibitors
Cannabinoids - pharmacology
Drug Interactions
Humans
Ion Channels - pharmacology
Piperidines - pharmacology
Pyrazoles - pharmacology
Receptors, Cannabinoid - drug effects
Receptors, Cannabinoid - physiology
TRPV Cation Channels
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cannabinoids, including the bioactive constituents of the marijuana plant, their synthetic analogs, and endogenous lipids with cannabinoid-like activity, produce their biological effects by interacting with specific receptors. To date, two G protein-coupled cannabinoid receptors have been identified by molecular cloning, CB1 receptors mainly expressed in the brain and mediating most of the neurobehavioral effects of cannabinoids and CB2 receptors expressed by immune and hematopoietic tissues. Recent findings indicate that some cannabinoid effects are not mediated by either CB1 or CB2 receptors, and in some cases there is compelling evidence to implicate additional receptors in these actions. These include transient receptor potential vanilloid 1 (TRPV1) receptors and as-yet-unidentified receptors implicated in the endothelium-dependent vasodilator effect of certain cannabinoids and in the presynaptic inhibition of glutamatergic neurotransmission in the hippocampus. The case for these additional receptors is being reviewed here.
ISSN:0163-7258
1879-016X
DOI:10.1016/j.pharmthera.2004.11.005